Gail Ward

Gail Ward is an experienced executive in the biopharmaceutical industry, currently serving as Executive Vice President at Samsung Biologics since September 2023. Previously, Gail held positions at ProKidney Corp. as Vice President from March 2022 to August 2023 and as Head of Quality from October 2016 to March 2022, contributing to the company's innovative renal cell therapy and its transition to Phase III trials. Earlier experience includes roles at Celltrion, where Gail was Vice President of Quality and Quality Support, leading efforts that resulted in significant biosimilar approvals, and as Associate Director of QA at Diosynth RTP, Inc. Additionally, positions at Biogen and Lederle-Praxis Biologics further developed expertise in quality assurance. Gail holds an Associate's degree in Applied Business Programming from Campbell University and has served as an independent consultant in the pharmaceutical and biologics sectors.